GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

narsoplimab   Click here for help

GtoPdb Ligand ID: 14317

Synonyms: narsoplimab-wuug | OMS-721 | OMS721 | Yartemlea®
Approved drug
narsoplimab is an approved drug
Compound class: Antibody
Comment: Narsoplimab (OMS721) is a fully human IgG4 monoclonal antibody against mannan-binding lectin-associated serine protease 2 (MASP-2) [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Ali YM, Ferrari M, Lynch NJ, Yaseen S, Dudler T, Gragerov S, Demopulos G, Heeney JL, Schwaeble WJ. (2021)
Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.
Front Immunol, 12: 714511. [PMID:34290717]
2. Dudler T, Yaseen S, Cummings WJ. (2023)
Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders.
Front Immunol, 14: 1297352. [PMID:38022610]
3. Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, Nakamura R, Sathar J, Ng E, Nangia N et al.. (2022)
Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.
J Clin Oncol, 40 (22): 2447-2457. [PMID:35439028]
4. Rambaldi A, Gritti G, Micò MC, Frigeni M, Borleri G, Salvi A, Landi F, Pavoni C, Sonzogni A, Gianatti A et al.. (2020)
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.
Immunobiology, 225 (6): 152001. [PMID:32943233]